

RECEIVED
CENTRAL FAX CENTER

001/006

JUL 20 2006

Atty Docket No. 021044-007310US

PTO FAX NO.: 1-571-273-0835

ATTENTION: Examiner Gary Nickol

Group Art Unit 16-6

**OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER Gary Nickol**

CERTIFICATION OF FACSIMILE TRANSMISSION


I hereby certify that the following documents in re Application of Brian Wong et al., Application No. 10/039,761, filed October 19, 2001 for MODULATORS OF LEUKOCYTE ACTIVATION, COMPOSITIONS AND METHODS OF USE are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Amendment after Allowance under 37 CFR §1.312(a)

Number of pages being transmitted, including this page: 6

Dated: July 20, 2006


Jo Ann Honcik Dallara for
Beth L. Kelly, Reg. 51,868

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: 415-576-0200
Fax: 415-576-0300
0860

60826844 v1

JUL 20 2006

I hereby certify that this correspondence is being sent via facsimile to Examiner Gary Nickol at 1-571-273-0835 addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On July 20, 2006

TOWNSEND and TOWNSEND and CREW LLP

By: 
Jo Ann Honcik Dallara

PATENT

Attorney Docket No.: 021044-007310US
Client Ref. No.: P.0061.01.US.UT.X00.RR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Brian Wong et al.

Application No.: 10/039,761

Filed: October 19, 2001

For: MODULATORS OF LEUKOCYTE ACTIVATION, COMPOSITIONS AND METHODS OF USE

Customer No.: 20350

Confirmation No. 9200

Examiner: Gary Nickol

Technology Center/Art Unit: 1646

AMENDMENT AFTER ALLOWANCE
UNDER 37 CFR § 1.312(a)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice of Allowance mailed October 28, 2005, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.